4161 related articles for article (PubMed ID: 35157371)
1. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
2. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial.
Furie RA; Morand EF; Bruce IN; Manzi S; Kalunian KC; Vital EM; Lawrence Ford T; Gupta R; Hiepe F; Santiago M; Brohawn PZ; Berglind A; Tummala R;
Lancet Rheumatol; 2019 Dec; 1(4):e208-e219. PubMed ID: 38229377
[TBL] [Abstract][Full Text] [Related]
3. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.
Furie R; Khamashta M; Merrill JT; Werth VP; Kalunian K; Brohawn P; Illei GG; Drappa J; Wang L; Yoo S;
Arthritis Rheumatol; 2017 Feb; 69(2):376-386. PubMed ID: 28130918
[TBL] [Abstract][Full Text] [Related]
4. Trial of Anifrolumab in Active Systemic Lupus Erythematosus.
Morand EF; Furie R; Tanaka Y; Bruce IN; Askanase AD; Richez C; Bae SC; Brohawn PZ; Pineda L; Berglind A; Tummala R;
N Engl J Med; 2020 Jan; 382(3):211-221. PubMed ID: 31851795
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 study.
Bruce IN; Nami A; Schwetje E; Pierson ME; Rouse T; Chia YL; Kuruvilla D; Abreu G; Tummala R; Lindholm C
Lancet Rheumatol; 2021 Feb; 3(2):e101-e110. PubMed ID: 38279367
[TBL] [Abstract][Full Text] [Related]
6. Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials.
Bruce IN; Furie RA; Morand EF; Manzi S; Tanaka Y; Kalunian KC; Merrill JT; Puzio P; Maho E; Kleoudis C; Albulescu M; Hultquist M; Tummala R
Ann Rheum Dis; 2022 Jul; 81(7):962-969. PubMed ID: 35580976
[TBL] [Abstract][Full Text] [Related]
7. Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials.
Bruce IN; van Vollenhoven RF; Psachoulia K; Lindholm C; Maho E; Tummala R
Lupus Sci Med; 2023 Jan; 10(1):. PubMed ID: 36639192
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of RNase therapy in systemic lupus erythematosus: a randomised phase 2a clinical trial of RSLV-132.
Burge DJ; Werth VP; Boackle SA; Posada J
Lupus Sci Med; 2024 Feb; 11(1):. PubMed ID: 38325898
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials.
Morand EF; Furie RA; Bruce IN; Vital EM; Dall'Era M; Maho E; Pineda L; Tummala R
Lancet Rheumatol; 2022 Apr; 4(4):e282-e292. PubMed ID: 38288923
[TBL] [Abstract][Full Text] [Related]
10. Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumab.
Strand V; O'Quinn S; Furie RA; Morand EF; Kalunian KC; Schwetje EG; Abreu G; Tummala R
Lancet Rheumatol; 2022 Mar; 4(3):e198-e207. PubMed ID: 38288936
[TBL] [Abstract][Full Text] [Related]
11. Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus.
Furie R; Morand EF; Askanase AD; Vital EM; Merrill JT; Kalyani RN; Abreu G; Pineda L; Tummala R
Lupus; 2021 Jul; 30(8):1254-1263. PubMed ID: 33977796
[TBL] [Abstract][Full Text] [Related]
12. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.
Vital EM; Merrill JT; Morand EF; Furie RA; Bruce IN; Tanaka Y; Manzi S; Kalunian KC; Kalyani RN; Streicher K; Abreu G; Tummala R
Ann Rheum Dis; 2022 Jul; 81(7):951-961. PubMed ID: 35338035
[TBL] [Abstract][Full Text] [Related]
13. Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus.
Chia YL; Zhang J; Tummala R; Rouse T; Furie RA; Morand EF
Rheumatology (Oxford); 2022 May; 61(5):1900-1910. PubMed ID: 34528084
[TBL] [Abstract][Full Text] [Related]
14. What Does It Mean to Be a British Isles Lupus Assessment Group-Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials.
Furie R; Morand EF; Bruce IN; Isenberg D; van Vollenhoven R; Abreu G; Pineda L; Tummala R
Arthritis Rheumatol; 2021 Nov; 73(11):2059-2068. PubMed ID: 33913260
[TBL] [Abstract][Full Text] [Related]
15. Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus.
Morand EF; Abreu G; Furie RA; Golder V; Tummala R
Ann Rheum Dis; 2023 May; 82(5):639-645. PubMed ID: 36690388
[TBL] [Abstract][Full Text] [Related]
16. Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial:
Morand EF; Trasieva T; Berglind A; Illei GG; Tummala R
Ann Rheum Dis; 2018 May; 77(5):706-713. PubMed ID: 29420200
[TBL] [Abstract][Full Text] [Related]
17. Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.
Morand E; Pike M; Merrill JT; van Vollenhoven R; Werth VP; Hobar C; Delev N; Shah V; Sharkey B; Wegman T; Catlett I; Banerjee S; Singhal S
Arthritis Rheumatol; 2023 Feb; 75(2):242-252. PubMed ID: 36369798
[TBL] [Abstract][Full Text] [Related]
18. Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar
Askanase AD; Wan GJ; Panaccio MP; Zhao E; Zhu J; Bilyk R; Furie RA
Rheumatol Ther; 2021 Mar; 8(1):573-584. PubMed ID: 33687687
[TBL] [Abstract][Full Text] [Related]
19. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.
Khamashta M; Merrill JT; Werth VP; Furie R; Kalunian K; Illei GG; Drappa J; Wang L; Greth W;
Ann Rheum Dis; 2016 Nov; 75(11):1909-1916. PubMed ID: 27009916
[TBL] [Abstract][Full Text] [Related]
20. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I).
Morand EF; Vital EM; Petri M; van Vollenhoven R; Wallace DJ; Mosca M; Furie RA; Silk ME; Dickson CL; Meszaros G; Jia B; Crowe B; de la Torre I; Dörner T
Lancet; 2023 Mar; 401(10381):1001-1010. PubMed ID: 36848918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]